World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 16 October 2023
Main ID:  NCT03568968
Date of registration: 14/06/2018
Prospective Registration: Yes
Primary sponsor: Haukeland University Hospital
Public title: A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease NOPARK
Scientific title: A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease: the NOPARK Study
Date of first enrolment: May 15, 2020
Target sample size: 400
Recruitment status: Recruiting
URL:  https://clinicaltrials.gov/ct2/show/NCT03568968
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).  
Phase:  N/A
Countries of recruitment
Norway
Contacts
Name:     Charalampos Tzoulis, MD, PhD
Address: 
Telephone:
Email:
Affiliation:  Haukeland University Hospital
Name:     Charalampos Tzoulis, MD, PhD
Address: 
Telephone: 94392305
Email: charalampos.tzoulis@helse-bergen.no
Affiliation: 
Key inclusion & exclusion criteria

Inclusion Criteria:

- Have a clinical diagnosis of idiopathic PD according to the MDS clinical diagnostic
criteria for Parkinson's disease

- [¹²³I]FP-CIT single photon emission CT (DaTscan) confirming nigrostriatal degeneration

- Diagnosed with PD within 2 years from enrolment

- Hoehn and Yahr score < 3 at enrolment

- Optimal symptomatic therapy, not requiring adjustments, for at least 1 month.

- Age equal to or greater than 35 years at time of enrolment.

Exclusion Criteria:

- Dementia or other neurodegenerative disorder at baseline visit

- Diagnosed with atypical parkinsonism or vascular parkinsonism

- Any psychiatric disorder that would interfere with compliance in the study.

- Any severe somatic illness that would make the individual unable to comply and
participate in the study.

- Use of high dose vitamin B3 supplementation within 30 days of enrolment

- Metabolic, neoplastic, or other physically or mentally debilitating disorder at
baseline visit.

- Genetically confirmed mitochondrial disease



Age minimum: 35 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Parkinson Disease
Intervention(s)
Other: Placebo
Dietary Supplement: Nicotinamide Riboside
Primary Outcome(s)
Disease severity assessed by the total MDS-UPDRS (Movement Disorder Society Unified Parkinson's Disease rating Scale) subsections I-III [Time Frame: 52 weeks]
Secondary Outcome(s)
Change in quality of life assessed by the EuroQuality of Life Five Dimensions (EQ-5D-5L) questionnaire. [Time Frame: 52 weeks]
Change in the clinical severity of cognitive decline assessed by the Montreal Cognitive Assessment (MoCA) scale [Time Frame: 52 weeks]
Change in the clinical severity of non-motor symptoms assessed by the Non-Motor Symptoms Assessment Scale [Time Frame: 52 weeks]
Change in the severity of nigrostriatal degeneration assessed by [¹²³I]FP-CIT single photon emission CT (DaTscan) [Time Frame: 52 weeks]
Secondary ID(s)
2017/2083
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history